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Objectives: Blood cardioplegia predominates in the adult because it provides 
superior myocardial protection, especially in the ischemically stressed 
heart. However, the superiority of blood over crystalloid cardioplegia n the 
pediatric population is unproved. Furthermore. because many pediatric 
hearts undergo a preoperative stress such as hypoxia, it is important o 
compare the different methods of protection in both normal and hypoxic 
hearts. Methods: Twenty neonatal piglets were supported by cardiopulmo- 
nary bypass and subjected to 70 minutes of cardioplegic arrest. Of 10 
nonhypoxic hearts, five (group 1) were protected with blood cardioplegia 
and five (group 2) with crystalloid cardioplegia (St. Thomas' Hospital 
solution). Ten other piglets underwent 60 minutes of ventilator hypoxia 
(inspired oxygen concentration 8% to 10%) before cardioplegic arrest. Five 
tgroup 3) were then protected with blood cardioplegia nd the other five 
(group 4) with crystalloid cardioplegia. Myocardial function was assessed 
by means of pressure volume loops and expressed as a percentage of 
control. Coronary vascular esistance was measured with each infusion of 
cardioplegic solution. Results: No difference waas noted between blood 
(group 1) or crystalloid cardioplegia (group 2) in nonhypoxic hearts 
regarding systolic function (end-systolic elastance 104% vs 103%). diastolic 
stiffness |156% vs 159%), preload recruitable stroke work ~102% vs 101%), 
or myocardial tissue edema (78.9% vs 78.9%). Conversely, in hearts 
subjected to a hypoxic stress, blood cardioplegia (group 3) provided better 
protection than crystalloid cardioplegia (group 4) by preserving systolic 
function (end-systolic elastance 106% vs 40%; p < 0.05) and preload 
recruitable stroke work (103% vs 40%;p < 0.05); reducing diastolic stiffness 
(153% vs 240%: p < 0.05) and myocardial tissue edema (79.6% vs 80.1%): 
and preserving vascular function, as evidenced by unaltered coronary 
vascular resistance (p < 0.05). Conclusion: This study demonstrates that (1) 
blood or crystalloid cardioplegia is cardioproteetive in hearts not compro- 
mised by preoperative hypoxia and (2) blood cardioplegia is superior to 
crystalloid cardioplegia in hearts subjected to the preoperative stress of 
acute hypoxia. (J Thorac Cardiovasc Surg 1997;113:994-1005) 
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L ow cardiac output after surgically induced isch- emia continues to be a major contributor to 
morbidity and mortality in pediatric cardiac sur- 
gery. t-4 The neonatal heart has a reduced systolic 
and diastolic functional reserve, as well as a reduced 
response to inotropic agents, compared with the 
adult heart, a' 3, 5, 6 Thus preservation of myocardial 
function in neonates during cardiac operations as- 
sumes even greater importance, because a periop- 
erative insult is less well tolerated and more difficult 
to treat. Although numerous tudies have compared 
blood cardioplegia with crystaltoid cardiop!egia in 
the mature heart, few have been done in the imma- 
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ture heart. 7-1° In addition, most studies have dem- 
onstrated conflicting results with no apparent differ- 
ence between these two methods of myocardial 
protection in infants. 2'8-1° Therefore, although 
blood cardioplegia predominates in adult patients 
undergoing cardiac operations, crystalloid cardio- 
plegia is still widely used in the pediatric popula- 
tion. 2 In view of the structural, functional, and 
metabolic differences, we believe that extrapolation 
of adult cardioplegia strategies to the neonate is 
imprudent.2, 3  7 Instead, we think the question of 
blood versus crystalloid cardioplegia must be stud- 
ied in the neonatal heart to resolve this continuing 
controversy. 
Most studies examining the question of blood 
versus crystalloid cardioplegia in the newborn infant 
have used an isolated heart preparation that does 
not mimic the clinical setting. 2' 8-10 These results 
may therefore be misleading and not clinically ap- 
plicable. In addition, these studies examined only 
normal (noninjured) neonatal hearts, whereas clin- 
ically many newborn hearts undergo a preoperative 
stress such as hypoxia, which alters the myocardium, 
rendering it more susceptible to a perioperative 
ischemic injury. ~-~5 In an attempt o address these 
concerns, this study compares blood versus crystal- 
loid cardioplegia using a clinically relevant model 
(simulating the operating room) in both nonhypoxic 
(noninjured) and hypoxic ("stressed") neonatal 
hearts. 
Material and methods 
Twenty neonatal piglets (5 to 16 days old; 3.5 to 5 kg) 
were premedicated with ketamine, 40 mg/kg given intra- 
muscularly, and anesthetized with pentobarbital, 30mg/kg 
given intraperitoneally and followed by 5 mg/kg given 
intravenously each hour. The lungs were ventilated via a 
tracheotomy with the use of a volume ventilator (Servo 
900B, Siemens-Elema, Solna, Sweden). All animals re- 
ceived humane care in compliance with the "Principles of 
Laboratory Animal Care" formulated by the National 
Society for Medical Research, and the "Guide for the 
Care and Use of Laboratory Animals," prepared by the 
National Academy of Sciences and published by the 
National Institutes of Health (NIH publication No. 96-03, 
revised 1996). 
The femoral artery and vein were cannulated to moni- 
tor arterial pressure, for blood gas determinations, and for 
intravenous infusions. After left thoracotomy, the coro- 
nary sinus was cannulated for blood sampling and pres- 
sure monitoring via the ligated hemiazygos vein. The 
heart was exposed by a median sternotomy, and transduc- 
er-tipped catheters (Millar Instruments, Inc., Houston, 
Tex.) were placed into the left ventricle, thoracic aorta 
(via the internal thoracic artery), left atrium, and pulmo- 
nary artery. The signals were routed to a recorder (model 
Table I. Warm blood cardioplegic solution 
Volume 
added Component Concentration 
Cardioplegia additive (ml) modif ied delivered* 
KC1 (2 mEq/ml) 10 K ÷ 8-10 mEq/L 
THAM (0.3 mol/L) 225 pH pH 7.5-7.6 
CPD 225 Ca ++ 0.2-0.3 mmol/L 
Aspartate/glutamate 250 Substrate 13 mmol/L each 
DsoW 40 Glucose >400 mg/dl 
DsW 200 Osmolarity 380-400 mOsm 
THAM, Tromethamine; CPD, citrate-phosphate-dextrose; Ds W,,50% 
dextrose inwater, DsW, 5% dextrose in water. 
*When mixed in 4:1 ratio with blood. 
4586C, Hewlett-Packard Company, Palo Alto, Calif.) by 
means of signal conditioners (model 8805C, Hewlett- 
Packard). A conductance catheter equipped with eight 
electrodes (Webster Laboratories, Baldwin Park, Calif.) 
was inserted through the left ventricular (LV) apex and 
the signals were routed to a Sigma-5 dual-field signal 
conditioner processor (Leycon, Cardiodynamics, Leiden, 
The Netherlands). After systemic heparinization (3 mg/ 
kg), a thin-walled venous cannula (18F) and an aortic 
cannula (8F) were inserted into the right atrial appendage 
and left subclavian artery, respectively. An 18-gauge car- 
dioplegia needle (DLP, Inc., Grand Rapids, Mich.) was 
inserted into the aorta for delivery of cardioplegic solu- 
tions. Arterial blood gases, electrolytes, and hemoglobin 
(Blood Gas System 288, Ciba Coming, Medfield, Mass.) 
were measured every 15 minutes to ensure optimal levels. 
A heating blanket was placed below the piglet, and a 
heating pad was placed on the abdomen to maintain a 
continuously monitored rectal temperature of 37 ° to 
38 ° C. All external heat sources were discontinued during 
systemic ooling (see Cardioplegia protocols). The cardio- 
pulmonary bypass (CPB) circuit was heparinized, primed 
with packed red cells from donor pigs, and in the blood 
cardioplegia group made normocalcemic with calcium 
chloride. The hematocrit value was adjusted to 25% to 
35% with 0.9% normal saline solution (Baxter Healthcare 
Corp., Deerfield, Ill.). A Shiley Plexus membrane oxygen- 
ator (Shiley, Inc., Irvine, Calif.) was used and the aortic 
pressure kept between 30 and 50 mm Hg by adjustment of
the systemic flow to approximately 100 ml/kg per minute. 
Cardioplegia protocols 
Blood cardioplegia. Cardioplegic solutions (CAPS Ser- 
vice, Research Medical Inc., Salt Lake City, Utah) are 
shown in Tables I and II. Cardioplegia was produced by 
the use of a protocol of 5 minutes of warm (37 °C) 
induction followed by 5 minutes of cold (4 ° C) induction, 
a 2-minute infusion of cold (4 ° C) cardioplegic solution 
every 20 minutes, and a 4-minute warm (37 ° C) cardiople- 
gic reperfusate ("hot shot") before aortic unclamping. 
Topical cooling with 4 ° C saline slush was applied during 
cold infusions and was removed before the warm reper- 
fusate was administered. Cardioplegic solution was in- 
fused at a continuously measured aortic pressure of 40 to 
50 mm Hg. Before the aorta was crossclamped, the piglets 
were cooled to 32 ° C. After warm induction the temper- 
ature was further lowered to 25 ° C, and rewarming to 
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Table I I .  Cold blood cardioplegic solution 
Volume 
Cardioplegia added Component 
additive (ml) modified 
Table I I I .  Composition of St. Thomas' Hospital 
(Plegisol) cardioplegic solution* 
KCI (2 mEq/ml) 10 K + 
THAM (0.3 mol/L) 200 pH 
CPD 50 Ca ++ 
DsW 1/4 NS 550 Osmolarity 
THAM, Tromethamine; CPD, citrate-phosphate-dextrose; DsW,, 5% dex- 
trose in water; NS, normal saline solution. 
*When mixed in 4:1 ratio with blood. 
Concentration Osmolarity (mOsm) 324 
delivered* pH pH 7.8 
8-10 mEq/L Potassium 16 mEq/L 
pH 7.6-7.8 Calcium 1,2 mmol/L 
0.5-0.6 mmol/L Magnesium 32 mEq/L 
340-360 mOsm Sodium 120 mEq/L 
Chloride 160 mEq/L 
37 ° C was begun 16 minutes before unclamping. CPB was 
discontinued 30 minutes after aortic unclamping, and final 
functional and biochemical measurements were made 30 
minutes later, after arterial blood gases, calcium, and 
potassium were normalized. 
Crystalloid cardioplegia. St. Thomas' Hospital solution 
(Plegisol, Abbott Laboratories, North Chicago, Ill.) was 
used for all infusions, and its composition is depicted in 
Table III. The cardioplegic solution was oxygenated and 
delivered at 4°C by means of this protocol: 20 mg/kg 
induction dose, 10 mg/kg every 30 minutes, and topical 
cooling with 4 ° C saline slush applied. Cardioplegic solu- 
tion was infused at a continuously measured aortic pres- 
sure of 40 to 50 mm Hg. Reperfusion was begun by 
maintaining CPB at a mean pressure of 20 mm Hg for 10 
minutes and then increased slowly to 30 to 50 mm Hg. 
Before the aorta was crossclamped, piglets were cooled to 
a systemic temperature of 28 ° C with the use of a hypocal- 
cemic prime. The temperature was further lowered to 
25 ° C once cardioplegia was begun, and gradual rewarm- 
ing to 37 ° C was begun 8 minutes before unclamping. CPB 
was discontinued 30 minutes after aortic unclamping, and 
final functional and biochemical measurements were 
made 30 minutes later, after arterial blood gases, calcium, 
and potassium were normalized. 
Physiologic measurements. Coronary vascular resis- 
tance (CVR) was determined uring each infusion of 
cardioplegic solution by measuring coronary sinus pres- 
sure and cardioplegia flow once a constant infusion rate 
with an aortic pressure between 40 to 50 mm Hg was 
achieved. CVR was calculated by the formula: 
CVR (dynes • see  -1  ° cm -5) = 
CIP - CSP 
× 80 
Cardioplegia flow 
where CIP = cardioplegia infusion pressure and CSP = 
coronary sinus pressure. 
Myocardial performance. LV pressure and conduc- 
tance catheter signals were amplified and digitized to 
inscribe LV pressure volume loops after first correcting 
for parallel conductance (myocardial tissue and blood 
viscosity) with the use of hypertonic saline solution ac- 
cording to the method of Baan, Van Der Velde, and 
Steendijk.16 A series of pressure volume loops was gener- 
ated under varying conditions by transient occlusion of the 
inferior vena cava during an 8-second period of apnea. 
*When mixed with 10 ml (10 mEq) of 8.4% sodium bicarbonate. 
Measurements were made before hypoxia or CPB (con- 
trol) and 30 minutes after CPB was discontinued. The 
end-systolic and end-diastolic pressure volume relation- 
ship and the preload recruitable stroke work relation. 
ship were analyzed with the use of a computer graphics 
program (Spectrum, Bowman-Gray School of Medi- 
cine, Winston-Salem, N.C.) on a 486-33 MHz Dell 
personal computer (Dell Computer Corp., Austin, 
Tex.). LV systolic performance was determined from 
the descending slope of the end-systolic pressure vol- 
ume relationship by means of linear regression analysis 
and designated as end-systolic elastance. End-diastolic 
compliance was determined from the exponential re- 
gression of the end-diastolic pressure volume relation- 
ship. Global myocardial performance was assessed by 
preload recruitable stroke work, which was calculated 
as the integral of LV transmural pressure and cavity 
volume over each cardiac cycle. Functional measure- 
ments are expressed as percent recovery of baseline 
values with each piglet acting as its own control. After 
final hemodynamic measurements, all piglets were  
again supported with CPB and cooled. Hearts were 
then arrested with cold (4 o C) cardioplegic solution and 
transmural LV biopsies obtained. Endocardial and epi- 
cardial portions were separated, frozen quickly in liquid 
nitrogen, and stored for biochemical analysis. A sepa- 
rate sample was obtained for myocardial water. 
Biochemical nalysis. Samples were crushed in a liquid 
nitrogen-cooled mortar and pestle and lyophilized (Sa- 
vant Speed Vac Systems, Farmingdale, N.Y.). The aden: 
osine pool was determined according to the method of 
Sarin and colleagues) 7 Ten to fifteen milligrams of dry 
tissue was extracted with 0.6 mol/L perchloric acid, the 
protein-free supernatant was neutralized by a mixture of 
KHCO 3 in 0.5 mol/L tromethamine (Tris) buffer (pH 7.5), 
and the neutralized solution was allowed to stand at 4 o C 
to precipitate KCLO4. Aliquots of the neutralized extract 
were analyzed with a high performance liquid chromato- 
graph (Waters Inc., Milford, Mass.) equipped with a 
Waters Nova-Pak column. The adenosine pool was iso- 
cratically eluted with a mobile phase consisting of 0.1 
mol/L ammonium phosphate (5.0 nmol/L) (tetrabutylam- 
monium hydroxide pH 5.0) and detected at 233 nml 
Adenosine triphosphate (ATP) levels are expressed as 
micrograms per gram dry tissue. 
Myocardial water. Ventricular samples were placed in 
a preweighed vial and dried to a constant weight at a 
temperature of 85 ° C. Myocardial water was calculated by 
means of the following formula: 
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Fig. 1. LV systolic function as measured by end-systolic elastance and expressed as a percentage of 
control. Note: There is complete preservation of systolic function independent of the type of cardioplegic 
solution used in noninjured (nonhypoxic) hearts. In hypoxic hearts, blood cardioplegic solution allowed for 
cellular repair of the hypoxic reoxygenation injury with complete return of systolic function. In contrast, 
systolic function is diminished in hypoxic hearts protected with a crystalloid cardioplegic solution. (See text 
for details.)*p < 0.0001. 
Percent myocardial water = 
Wet weight - Dry weight 
x 100 
Wet weight 
Experimental groups 
Nonhypoxemic (uninjured hearts) studies. After CPB 
was begun, 10 piglets underwent 70 minutes of cardiople- 
gic arrest with either the blood (group 1, n = 5) or 
crystalloid (group 2, n = 5) cardioplegia protocol outlined 
herein. 
tIypoxemic (stress) studies. Ten other piglets underwent 
60 minutes of ventilator hypoxia by lowering the frac- 
tion of inspired oxygen to 8% to 10%, producing an 
arterial oxygen tension of 25 to 35 mm Hg and an 
oxygen saturation of 65% to 70%. Before hypoxemia, 
piglets were given transfusions as necessary to increase 
the hematocrit value to greater than 35%. This condi- 
tion simulates the chronic adaptive change of erythro- 
cytosis that occurs in the cyanotic infant and increases 
oxygen-carrying capacity, thereby allowing ischemia to 
be avoided during hypoxia. All piglets remained in 
hemodynamically stable condition during the entire 60 
minutes of ventilator hypoxia. At the end of 60 minutes, 
all piglets were placed on CPB at an inspired oxygen 
concentration of 100% to produce a reoxygenation 
injury.is, 19 The aorta was clamped and piglets under- 
went 70 minutes of cardioplegic arrest with either the 
blood (group 3, n = 5) or crystalloid (group 4, n = 5) 
cardioplegia protocol outlined earlier. 
Statistics. Data were analyzed by means of JMP V2.0 
(SAS Institute, Inc., Cary, N.C.) on a Macintosh IIVX 
computer (Apple Inc., Cupertino, Calif.). Paired Student's 
t test and two-way analysis of variance with interaction 
(factorial analysis) were used for comparison of vari- 
ables among experimental groups. If the analysis of 
variance revealed a significant interaction, pairwise 
tests of individual group means were compared by 
K 
means of multiple comparisons (Tukey's test). Group 
data are expressed as mean z standard error of the 
mean. Values of p < 0.05 were considered to be 
statistically significant. 
Results 
No difference between groups was noted for 
control values of LV contractility, diastolic compli- 
ance, or global myocardial function. Hypoxia re- 
sulted in an increase in heart rate from 130 to 150 
beats/rain up to 190 to 220 beats/rain, decreased 
systemic vascular esistance index, increased pulmo- 
nary vascular esistance index, and did not signifi- 
cantly affect cardiac output. All piglets tolerated 60 
minutes of hypoxia with stable hemodynamics. 
Hemodynamics and physiologic measurements. 
Results are seen in Figs. 1 through 5. There was no 
change or difference in the X intercept (V0) for 
end-systolic elastance or preload recruitable stroke 
work between prebypass (control) and postbypass 
values in any experimental group. Therefore the 
change in slope of end-systolic elastance, preload 
recruitable stroke work, and diastolic compliance 
can be interpreted to express variability in the 
contractile state of the myocardium compared with 
control values. In nonhypoxic hearts, no difference 
> 0.05) was found between blood (group 1) or 
crystalloid cardioplegia (group 2) regarding postby- 
pass systolic function (end-systolic elastance 104% 
_+ 4% vs 103% _+ 1%), diastolic stiffness (156% _+ 
5% vs 159% _+ 3%), or preload recruitable stroke 
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Fig. 2. LV diastolic ompliance as measured by end-diastolic pressure volume relationship and expressed 
as a percentage ofstiffness compared with control. Note: There is only minimal increase in diastolic stiffness 
in noninjured (nonhypoxic) hearts independent of the type of cardioplegic solution used. In hypoxic hearts, 
blood cardioplegic solution allowed for cellular epair of the hypoxic reoxygenation injury, resulting in only 
mild increase in diastolic stiffness, which is not statistically different from noninjured hearts. Conversely, 
there was a marked increase in diastolic stiffness in hypoxic hearts protected with a crystalloid cardioplegic 
solution. (See text for details.) *p < 0.0001. 
work (102% _+ 2% vs 101% _+ 1%) (Figs. 1 to 3). 
Conversely, in hearts subjected to prebypass hyp- 
oxia, blood cardioplegia (group 3) provided superior 
protection by preserving systolic function (end-sys- 
tolic elastance 106% _+ 3% vs 40% +_ 1%; p < 
0.0001) and preload recruitable stroke work (103% 
_+ 1% vs 40% _+ 1%; p < 0.0001) and reducing 
diastolic stiffness (153% +_ 12% vs 240% _+ 4%:p < 
0.0001) compared with crystalloid cardioplegia 
(group 4) (Figs. 1 to 3). There was no change in 
CVR during cardioplegic infusions in hearts receiv- 
ing blood cardioplegia with or without preceding 
hypoxia (Fig. 4). In contrast, although lower in both 
crystalloid groups, CVR rose markedly in hypoxic 
hearts receiving crystalloid cardioplegia (group 4), 
indicating vascular dysfunction (Fig. 5). 
Tissue studies. Results are summarized in Table 
IV. Although no statistically significant difference in 
ATP was noted among the four groups, ATP levels 
were lowest in hypoxic hearts protected with a 
crystalloid cardioplegic solution (group 4). How- 
ever, a significant interaction between stress (hyp- 
oxia) and type of cardioplegic solution was noted for 
the ratio of adenosine tripnosphate to diphosphate 
(ATP/ADP) (F 6.5, p = 0.02). This ratio, which 
reflects the ability of the mitochondria to phosphor- 
ylate ADP to ATP, was markedly reduced in both 
groups of hearts protected with a crystalloid car- 
dioplegic solution (groups 2 and 4), suggesting mi- 
tochondrial damage, especially in hypoxic hearts 
(group 4). There was also a significant interaction 
for myocardial water (F - 5.1, p - 0.04). Although 
the highest amount of cellular water (80.1% + .1%) 
was found in hypoxic hearts protected with crystal- 
loid cardioplegia (group 4), indicating the greatest 
degree of cellular injury, there was no statistically 
significant difference between this group and hy- 
poxic hearts subjected to blood cardioplegia (80.1% 
vs 79.6%) 
Discussion 
This study demonstrates that in the clinically 
relevant intact animal model simulating operating 
room conditions, (1) blood and crystalloid cardio- 
plegia both provide good myocardial protection of 
neonatal hearts not subjected to a preoperative 
stress, (2) hypoxic (stressed) neonatal hearts are 
more dependent on the type of cardioplegic protec- 
tion, and (3) the optimal method of myocardial 
protection of hypoxically "stressed" hearts is 
achieved with blood cardioplegia. 
In contrast to studies in the adult, most studies 
conducted in newborn infants have shown little 
difference between blood and crystalloid cardiopte- 
gia.2, s-10 This inability to demonstrate a difference 
may be due to various factors. Unlike adult studies. 
most neonatal investigations have used an isolated 
heart model, z' 8-10 Although this allows for precise 
experimental control, it does not mimic clinical 
conditions of the operating room. For instance. 
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Fig. 3. Overall LV myocardial function as measured by preload recruitable stroke work and expressed as 
a percentage of control. Note: There is complete preservation ofglobal myocardial function independent 
of the type of cardioplegic solution in noninjured (nonhypoxic) hearts. In hypoxic hearts, blood 
cardioplegic solution allowed for cellular repair of the hypoxic reoxygenation i jury with complete 
preservation of global myocardial function. In contrast, here is depressed global myocardial function in 
hypoxic hearts protected with a crystalloid cardioplegic solution, indicating cellular damage. (See text for 
details.) *p < 0.0001. 
bronchial blood return and noncoronary collateral 
flow are absent in the isolated heart but may have a 
profound effect in the in vivo model, because the 
cardioplegic solution may be washed away, changing 
the cellular environment] Hypothermia, which may 
provide the dominate protective ffect, is easier to 
maintain in the isolated heart preparation, whereas 
the heart is constantly rewarmed in the intact animal 
setting.2, 3, 8 Furthermore, despite the prevalence of 
preoperative stresses such as hypoxia in the neonatal 
population, few studies have included such hearts in 
their investigations. However, hypoxia has been 
shown to significantly alter the myocardium and 
affect cardioplegic protection. Therefore we exam- 
ined blood and crystalloid cardioplegia in neonatal 
hearts using (1) a model that mimics operating room 
conditions and (2) noninjured (nonhypoxic) and 
hypoxic (stressed) neonatal hearts. 
In nonhypoxic (noninjured) hearts, myocardial 
function was completely preserved with either car- 
dioplegic solution (see Figs. 1 to 3). Myocardial 
edema and ATP levels were also unchanged, indi- 
cating that the two cardioplegic solutions provide 
similar protection. However, in this study the isch- 
emic (crossclamp) time was relatively short, and the 
neonatal myocardium is more tolerant of ischemia 
than the adult. 2' 3 Inasmuch as a reperfusion i jury is 
dependent on the duration of ischemia, these factors 
may have accounted for the lack of difference seen 
between these two groups. 7It is possible that differ- 
ences may have been seen had the crossclamp time 
been extended, especially since the ATP/ADP ratio 
was significantly reduced in both crystalloid groups 
(see Table IV). Furthermore, in clinical practice 
congenital lesions usually result in hypoxia or pres- 
sure-volume overload; therefore "normal" hearts 
are probably uncommon, especially in the neonatal 
population. 
An increasing number of infants with cyanotic 
congenital heart disease are undergoing primary 
repair. 2'3 Although repair may be preferable to 
palliation, it subjects the immature hypoxic heart to 
high oxygen levels during CPB, a condition that has 
been shown to cause an unintended reoxygenation 
injury.iS, 19 This injury, which is mediated by oxygen- 
derived free radicals, results in myocardial depres- 
sion and may explain the reason for myocardial 
necrosis and impairment of ventricular function 
after apparently successful surgical correction of 
cyanotic congenital defects. 6'14'1s-2° Despite the 
prevalence of hypoxia in the neonatal population, 
no studies have examined the question of blood 
versus crystalloid cardioplegia n a clinically relevant 
(stressed) hypoxic model. Including stressed hearts 
in any investigation of cardioplegic solutions is 
important because the results can be dramatically 
altered.9, 11, 13 This is the reason that adult studies of 
various cardioplegic solutions imposed a preisch- 
emic stress] However, because pediatric hearts do 
not usually experience severe preoperative ischemia, 
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Fig. 4. CVR in hypoxic and nonhypoxic hearts measured uring each blood cardioplegi c infusion. 
Cardioplegic nfusions 1 and 4 were during warm (37 ° C) induction and reperfusion, respectively, and 2 and 
3 were during cold (4 ° C) multidose infusions. Note: There is no difference (p > 0.05) i n CVR in hearts 
protected with a blood cardioplegic solution, indicating that blood cardioplegia preserves vascular function 
despite a hypoxic stress. (See text for details.) 
the injury must be changed to reflect a clinically 
relevant stress, such as hypoxia. 
Subjecting the neonatal piglet to acute hypoxia 
profoundly altered the effect of the cardioplegic 
solutions on the myocardium. Blood cardioplegic 
solutions not only protected the heart from further 
damage but also facilitated repair of the injury 
caused by hypoxia and reoxygenation, resulting in 
complete preservation of myocardial and vascular 
function (see Figs. 1 to 4). Conversely, a cellular 
injury occurred in hypoxic hearts protected with 
crystalloid cardioplegic solutions. This injury was 
manifest by depression in postbypass myocardial 
and vascular function (see Figs. 1 to 3 and Fig. 5). 
Although our model of acute hypoxia does not allow 
for the chronic adaptive changes that may occur in 
cyanotic newborn infants, it does subject he heart to 
a clinically relevant "stress." Several studies have 
documented a similar oxygen-mediated injury with 
reoxygenation of the ch.ronically hypoxic infant, and 
we recently documented an identical injury in 21 
cyanotic infants using the same biochemical test as 
our acute experimental studies.2123 In addition, our 
results demonstrating an increased sensitivity to 
crystaltoid cardiQPlegia fter acute hypoxia are sim- 
ilar to those obtained in piglets subjected to chronic 
hyp0xiall, 12 and to those obtained in cyanotic in- 
rants,l, 2, 14 leading us to believe our experimental 
findings are clinically relevant. 
Vascular function was determined by measuring 
CVR during each infusion of cardioplegic solution 
when the heart was arrested and the flow rate and 
infusion pressure were constant. Although the CVR 
may change between warm and cold cardioplegia 
and between blood and crystalloid cardioplegia, it 
should be identical for each solution at a given 
temperature because our experimental model of 
hypoxia does not result in ischemia. This is exactly 
what was seen in piglets protected with blood car- 
dioplegia: no difference in CVR was detected be- 
tween hypoxic and nonhypoxic hearts, indicating 
preservation of vascular function despite an acute 
hypoxia stress injury (see Fig. 4). tn contrast, al- 
though the CVR was lower in the crvstalloid groups 
because of the lower viscosity, there Was a marked 
increase in CVR in hypoxic hearts during each 
infusion of cardioplegic solution (group 4), implying 
that vascular function was compromised (see Fig. 5). 
The only other reason for this increased CVR would 
be vascular compression from increased myocardial 
water. However. no significant difference in myocar- 
dial edema was noted between blood-perfused and 
crystalloid-perfused hearts subjected to hypoxia. 
Therefore, CVR was increased only in hypoxic 
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Fig. 5. CVR in hypoxic and nonhypoxic hearts measured uring each crystalloid cardioplegic nfusion. All 
cardioplegic nfusions were delivered cold (4 ° C). Note: There is a marked rise in CVR when a crystalloid 
cardioplegic solution is used in hypoxic hearts, indicating a derangement i  vascular function. (See text for 
details.) *p = 0.001. 
hearts subjected to crystalloid cardioplegia, a fact that 
supports a derangement in vascular function, not 
edema. Furthermore, this increased CVR may have 
resulted in less homogeneous distribution of the car- 
dioplegic solution during ischemia, thereby compro- 
mising myocardial protection during cardiac arrest. 
We did not measure vascular function after discon- 
tinu~ag CPB. However, because myocardial function 
was still depressed after CPB in hypoxic hearts pro- 
tected with a crystalloid cardioplegic solution, it is 
likely that vascular function was similarly affected. 
Blood cardioplegia has several advantages over 
crystalloid cardioplegia which help to explain our 
findings] The heart is arrested in an oxygenated 
environment so that no toss of high-energy phos- 
phate stores occurs during the short period of 
electromechanical activity before asystole. 7 Several 
investigators have reported significant decreases in 
high-energy phosphates during the few heartbeats 
occurring during induction with crystalloid cardio- 
plegia. Because the hypoxic heart has been shown 
both clinically and experimentally to have an in- 
creased susceptibility to ATP depletion during sur- 
gically induced ischemia, this may be partially re- 
sponsible for the improvement seen in the blood 
cardioplegia groups. 12' 14 When given as a warm 
induction, blood cardioplegic solutions can "resus- 
citate" the injured myocardium, thereby allowing it 
to better tolerate the imposed period of surgical 
Table IV. Endocardial t&sue results 
ATP 
(txg/gm ATP/ADP 
Group tissue) ratio Water (%) 
Normal (nonhypoxic) 15.8 _+ 0.4 4.3 -+ 0.3 78.9 ± 0.4 
heart/blood (group 1) 
Normal (nonhypoxic) 15.6 _+ 0.7 3.3 _+_ 0.4* 78.9 + 0.2 
heart/crystalloid 
(group 2) 
Hypoxic heart/blood 15.3 -+ 1.1 4.1 -+ 0.2 79.6 _+ 0.6 
(grottp 3) 
Hypoxic heart/ 13.3 ~ 0.8 2.6 ± 0.4? 80.1 + 0.1:) 
crystalloid 
(group 4) 
*p < 0.05 versus blood cardi0plegia hearts (groups 1 and 3). 
tp < 0:05 versus all other groups (groups 1, 2, and 3). 
,+p < 0.05 versus normal hearts (groups 1 and 2). 
ischemia.7, 24 Blood eardioplegic solutions also pro- 
vide oxygen and nutrients during muttidose infu- 
sions to enhance cellular metabolism and replenish 
depleted energy storage. 7 Last, because the hypoxic 
heart may be more susceptible to a reperfusion 
injury after ischemia, use of a warm reperfusate (hot 
shot ) can modify this injury before the aortic cross- 
clamp is removed, y'25 
Tissue ATP levels seem to support this hypothe- 
sis. In both blood cardioplegia groups, ATP levels 
and the ATP/ADP ratio remained unaffected e- 
spite the stress of preoperative hypoxia (see Table 
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IV). Conversely, although crystalloid cardioplegia 
was able to maintain ATP levels in normal hearts, 
the high-energy phosphates were reduced in those 
hearts subjected to preoperative hypoxia. In addi- 
tion, the ATP/ADP ratio fell in all piglets protected 
with crystalloid cardioplegia, especially those sub- 
jected to hypoxia (group 4). This seems to indicate 
that mitochondrial damage resulting in a decreased 
ability to convert ADP to ATP is indeed present. 
These findings parallel those seen clinically in pa- 
tients with tetralogy of Fallot, in whom ATP levels 
are significantly depressed and decreased ventricu- 
lar function is often present after surgical correc- 
tion.6, 12,14, 2o In addition, because low postischemic 
ATP levels in infants correlate with poor postoper- 
ative ventricular function, these findings, along with 
the functional data, suggest hat crystalloid cardio- 
plegia provides inadequate protection in hypoxic 
hearts)l, 15 Unlike ischemic models, our experimen- 
tal model of acute hypoxia does not cause significant 
depletion of nucleotide stores (unpublished ata). 
However, chronically cyanotic hearts may be predis- 
posed to accelerated epletion of these high-energy 
compounds during periods of increased myocardial 
oxygen demands associated with exercise or surgi- 
cally induced ischemia during operative repair) < 27 
Therefore the effects of crystalloid cardioplegic so- 
lutions may even be more pronounced in the clinical 
setting and may explain why myocardial necrosis is 
common after repair of cyanotic congenital heart 
defects. 14 
We did not test every crystalloid cardioplegic solu- 
tion or strategy currently available. The optimum 
crystalloid cardioplegic solution was not the aim of the 
current study. The crystalloid cardioplegic solution and 
strategy used was chosen because it has been exten- 
sively investigated and is advocated by surgeons at the 
Boston Children's Hospital. 2' 9,11, 2g Unlike other in- 
vestigators, we chose to deliver each cardioplegic 
solution as it is delivered clinically, using those strate- 
gies that have been shown to optimize protec- 
tion.2, 7,11, 2,, 29 Therefore the protocols for blood and 
crystalloid cardioplegia differed slightly. Although us- 
ing identical cardioplegic protocols may be preferred 
scientifically, it does not allow one to test each solution 
to its maximal clinical potential. For instance, both 
warm induction and reperfusion were used for blood 
cardioplegia because these methods have been shown 
to improve protection in stressed adult hearts] In 
contrast, no warm crystalloid infusions were given, 
because no such benefits have been demonstrated. To 
maximize crystalloid protection, hearts were cooled 
with the use of a hypocalcemic bypass prime; the 
cardioplegic solution was oxygenated and delivered at 
a low pressure: the heart was kept cool with topical 
(4 ° C) cooling; and reperfusion was begun at 20 mm 
Hg and increased slowly. It is possible that had other 
crystalloid solutions or strategies been used. different 
results may have been obtained. However. because we 
incorporated all of the strategies that have been shown 
to optimize crystalloid cardioplegia protection and 
administered the solution as recommended bynumer- 
ous clinical and experimental investigators, we believe 
our method represents a fair comparison. 2 7. 9. 11.28.29 
In summary, this study demonstrates that in a 
clinically relevant model both blood and crystalloid 
cardioplegia provide excellent myocardial protec- 
tion in nonhypoxic (noninjured) hearts subjected to 
a short ischemic interval. Conversely, when the 
heart is subjected to a preoperative hypoxic stress, 
the type of cardioplegia takes on an increased 
importance, with blood cardioplegia providing supe- 
rior myocardial protection. Because cyanotic hearts 
are often depressed after apparently successful sur- 
gical repair, this study suggests that a blood car- 
dioplegic solution should be used to ensure optimal 
protection. 
We gratefully acknowledge Ms. Peggy Burse and Ms. 
Kym Montecinos, for their organizational nd secretarial 
assistance, and Dibyen Majumdar, PhD, for statistical 
consultation. 
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Discussion 
Dr. Davis C. Drinkwater (Los Angeles, Calif.). Using a 
neonatal piglet model, Dr. Bolling and his colleagues from 
University of Illinois have demonstrated the superiority of 
blood cardioplegia over crystalloid cardioplegia (St. 
Thomas' Hospital) in preinjured hypoxic pediatric hearts. 
An intermittent ischemic time of 70 minutes in uninjured 
hearts showed no such benefit. My comments and ques- 
tions are limited to the abstract and the presentation 
because I have not had the benefit of previewing the 
manuscript. I am sure the article itself will further eluci- 
date many of the issues that I am going to raise. 
First let me commend you on your study, which further 
adds to the information concerning benefits of blood 
cardioplegia in pediatric hearts. Previous work by my 
colleagues and me, as well as others, both in intact and 
isolated piglet heart models, found that a hypoxic insult of 
an oxygen tension in the range of 25 mm Hg was required 
to significantly acutely preinjure the neonatal heart, which 
is extremely adaptive under hypoxic conditions and in an 
acute model. These also required substrate repletion 
(glutamate and aspartate). How do you account, Dr. 
Bolling, for the fact that the rather moderate hypoxia that 
you used caused so profound an injury? Did you have an 
opportunity to measure any tissue levels of energy sub- 
strates, such as glucose or ATP? 
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Dr. Boiling. Our model of acute hypoxia results in a 
"stress" injury, which is similar to the injury reported by 
Del Nido and colleagues after reoxygenation of cyanotic 
infants undergoing repair of tetralogy of Fallot. This 
injury may be less severe than other experimental models, 
but it does allow us to test cardioplegic solutions using 
stressed neonatal hearts subjected to oxygen saturations 
that are similar to those seen in hypoxic newborn infants. 
The fact that we saw differences between cardioplegic 
solutions in these less injured hearts may mean that the 
differences might have been even more pronounced had 
we used a more severe injury. Furthermore, we demon- 
strated in a previous eries of experiments hat our model 
of acute hypoxia does not result in ischemia. The reason is 
that piglets are given transfusions before acute hypoxia to 
simulate the chronic adaptive change of erythrocytosis, 
thereby increasing oxygen-carrying capacity. Evidence for 
the adequacy of cellular oxygen during hypoxia in these 
experiments was demonstrated by oxygen consumption 
data, lack of lactate production, and preservation of ATP 
levels. Therefore, unlike your hypoxic insult, our model of 
hypoxia does not result in significant substrate depletion. 
However, in cyanotic hildren ATP may be depleted as a 
result of exercise or stress, either before or during oper- 
ative repair. Because ATP depletion is known to lead to 
postoperative myocardial depression and may subject he 
heart to a reperfusion injury as well as a reoxygenation 
injury, cyanotic infants may be even more dependent on 
the type of cardioplegic protection. We also measured 
postbypass ATP levels (see Table IV). These results 
demonstrate depression of ATP and the ATP/ADP ratio 
in hypoxic piglets protected with a crystalloid cardioplegic 
Solution, suggesting that these hearts were not protected 
as well as hearts given blood cardioplegia. 
Dr. Drinkwater. Second, I have some technical ques- 
tions cdncerning the comparability of the protocols used 
in the solutions and the technique of myocardial preser- 
vation. Inasmuch as each heart was used as its own 
control, at what point (before or after hypoxia) were 
measurements taken, given recovery percentages greater 
than 100% Of the control? 
Dr. Boiling. Measurements were made before CPB or 
any hypoxic intervention and 1 hour after removal of the 
aortic crossclamp. The greatest recovery was 106% of 
control, which is not statistically different from the preby- 
pass values. 
Dr. Drinkwater. Was there any difference after hyp- 
oxia? 
Dr. Boiling. Hypoxia resulted in an increase in heart 
rate from 130 to 150 beats/min up to 190 to 220 beats/min, 
decreased systemic vascular resistance index, increased 
pulmonary vascular esistance index, and did not signifi- 
cantly affect cardiac output. All piglets tolerated 1hour of 
hypoxia with stable hemodynamics. 
Dr. Drinkwater. You mentioned that you administered 
the blood cardioplegic solution every 20 minutes and the 
crystalloid solution every 30 minutes. Why was the time 
period used for the the two groups not more comparable? 
Dr, Boiling, As extensively discussed in the manuscript, 
we chose to deliver each cardioplegic solution as recom- 
mended by numerous experimental nd clinical investiga- 
tors, using those strategies that have been shown to 
optimize protection with each method Although using 
identical cardioplegic protocols may be preferred scientif- 
ically, it does not allow one to test each solution to its 
maximal clinical potential. Furthermore. if we had fol- 
lowed the same protocol for both solutions, which proto- 
col should we have chosen, one designed primarily for 
blood or one designed primarily for crystalloid cardiople- 
gia? For instance, if we used a protocol developed for 
blood cardioplegia which included warm induction and 
warm reperfusion, we would correctly have been criticized 
for delivering crystalloid cardioplegia in a detrimental 
manner. However. avoiding the use of warm induction in 
both groups does not answer the question of which 
solution is better, because the two solutions are not used 
to their full advantage. Therefore blood cardioptegia was 
given every 20 minutes and crystalloid every 30 minutes. 
because these protocols have been recommended to 
achieve optimal protection with each method. Many in- 
vestigators have also noted that multidose crystalloid 
cardioplegia may offer no advantage over a single dose. 
and may indeed be detrimental. To maximize crystalloid 
protection with less frequent infusions, we maintained 
hypothermia by lowering bypass temperature to 25 ° C, 
room temperature to 18 ° C. and using topical 4 ° C cooling. 
Although we considered administering the crystalloid 
cardioplegic solution more frequently, we were concerned 
that we would then be criticized by those investigators who 
have demonstrated that frequent multidose crystalloid 
cardioplegic infusions can be detrimental. Therefore we 
chose to deliver each solution as it is given in most 
experimental nd clinical studies. 
Dr. Drinkwater. What about he use of topical cooling? 
Your abstract states that you packed the heart in ice. Is 
that actually clinically relevant given our concerns for 
phrenic nerve injuries and other problems? 
Dr. Boiling. We apologize for this inaccuracy in our 
original abstract. The heart was not packed in ice. Instead, 
4 ° C cold saline slush was applied to all hearts. This has 
not been shown to cause phrenic nerve injury in infants. 
and it is extensively used, especially by surgeons using 
crystalloid cardioplegia. In addition, if this had caused 
myocardial injury, we would have expected it to affect both 
blood and crystalloid groups equally. However. functional 
recovery was complete in hypoxic hearts protected with 
blood cardioplegia, whereas hearts protected with crystal- 
loid cardioplegia showed marked depression. 
Dr. Drinkwater. Did you control for calcium levels. 
particularly during reperfusion? 
Dr. Boiling. Yes. we did. In the crystalloid groups a 
hypocalcemic bypass prime was used both for cooling and 
for reperfusion. Although a normocalcemic bypass prime 
was used in the blood cardioplegia groups, the cardiople- 
gic solution was made hypocalcemic by the addition of 
citrate, as depicted in Tables I and II. 
Dr. Drinkwater. Third. vascular eactivity as a measure- 
ment of coronary vascular resistance has been interpreted 
in your study as endothelial cell function. Although this is 
quite possible, can you really conclude this in the absence 
of provocative ndothelium-dependent and -independent 
stimulation and the absence of. say. nitric oxide measure- 
ments, especially given the variability of the viscosity of 
your solutions? 
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Dr. Boiling. We agree that we cannot identify the site of 
the vascular dysfunction on the basis of our results. Although 
we believe it is most likely due to a vascular endothelial cell 
injury, this cannot be proved with our data. 
Dr. Drinkwater. Let me conclude by noting that prior 
studies in our laboratory over 10 years ago showed in an 
isolated piglet model that intermittent ischemia of 120 
minutes had better ecovery with blood cardioplegia over 
St. Thomas solution, and particularly if we added gluta- 
mate to the blood cardioplegic solution. In your model, 70 
minutes may be adequate for most procedures, but may 
not reflect the more complex procedures uch as LV 
outflow tract reconstruction. In very experienced hands, 
the left-sided aspect of the pulmonary autograft proce- 
dures routinely requires over 100 minutes of crossclamp 
time. Therefore it is possible that had you used a greater 
ischemic time, particularly in normal hearts, there might 
have been differences in recovery between these two 
solutions. Would you comment on this and, most impor- 
tant, on whether your group has adopted a selective 
approach to the noncyanotic patients in terms of car- 
dioplegic management? 
Dr. Bolling. We agree that 70 minutes may not be 
adequate to perform all complex neonatal myocardial 
repairs. In addition, because the neonatal myocardium 
may be more tolerant o ischemia than the adult myocar- 
dium, we believe that differences would probably have 
been seen had the crossclamp time been extended, espe- 
cially since the ATP/ADP ratio was significantly reduced 
even in "normal" (nonhypoxic) hearts protected with 
erystalloid cardioplegia. Furthermore, in clinical practice 
congenital esions usually result in either hypoxia or 
pressure-volume overload, and therefore "normal" hearts 
are probably uncommon, especially in the neonatal pop- 
ulation. Because of these concerns, our group has not 
adapted a selective approach, and we use blood cardio- 
plegia exclusively. 
Dr. Pat O. Daily (San Diego, Calif.). Why did you use 
topical cooling in the pericardium with crystalloid cardio- 
plegia and no myocardial surface cooling in the blood 
cardioplegia group? 
Dr. Boiling. We apologize for the confusion on this 
issue. Although our original abstract mentions topical 
cooling only in the crystalloid cardioplegia group, we 
applied topical cooling to all hearts to try to make the 
groups as similar as possible. 
Dr. Daily. My concern is that you mention ice slush as 
opposed to just cold saline solution. Could the addition 
of this ice have caused some of the injury to these 
hearts? 
Dr. Boiling. Although the topical cooling was primarily 
cold saline solution, it did contain some particles of ice, 
making it somewhat of a slush solution. However, when 
we measured the temperature ofthe solution it was almost 
always approximately 4 °C, which has not been shown to 
be detrimental. In addition, had the ice particles been 
responsible for causing damage, we would have expected 
both groups to be affected equally. In contrast, only 
hypoxic hearts protected with a crystalloid cardioplegic 
solution showed any decrease in ventricular function. 
Therefore we do not believe the small quantity of ice in 
the topical saline solution was the reason for these results. 
Dr. Gregory Misbach (San Bernardino, Calif.). I have 
one related question. Inasmuch as I used 20-minute 
intervals for either crystalloid or blood cardioplegia over 
the years, I would be suspicious that a 30-minute interval 
might introduce another variable when trying to investi- 
gate the differences between crystalloid and blood cardio- 
plegia. Are you able to deal with this issue? 
Dr. Bolling. As mentioned in our discussion of Dr. 
Drinkwater's question and the manuscript, we chose these 
time intervals on the basis of the experience of numerous 
investigators. Blood cardioplegia was given every 20 min- 
utes, as is widely accepted. Conversely, numerous investi- 
gators have demonstrated that multidose crystalloid car- 
dioplegia may not be beneficial, and can be potentially 
detrimental when given too frequently. Therefore we 
chose the 30-minute interval, as advocated by most clinical 
and experimental investigators. We were concerned that 
had we given crystalloid cardioplegia every 20 minutes, we 
would have instead been criticized for possibly injuring 
the hearts as a result of frequent administrations. 
Dr. Misbaeh. By showing a change in vascular eactivity 
between the two groups, are you speculating that this 
might be a contributing mechanism to poor myocardial 
protection; that perhaps there was more even distribution 
of delivery of the cardioplegic solution because of the 
different vascular reactivity in the blood cardioplegia 
group? 
Dr. Boiling. We believe that this increase in CVR 
during the infusion of crystalloid cardioplegia in hypoxic 
hearts probably represents an injury to vascular function. 
This increased CVR in the crystalloid group may result in 
less homogeneous cardioplegic distribution during the 
period of ischemia nd, therefore, may compromise myo- 
cardial protection. 
